KCS

Commercialization of innovative drugs is a long journey of more than 10 years from basic discovery to marketing approval from health authorities. And it requires multi-disciplinary team covering basic research, medicinal chemistry, process chemistry, clinical science, and regulatory capabilities. In the meantime, drug discovery and drug development require differing skillsets, expertise and culture.

NRDO, No Research Development Only, is a business model for drug development, and focuses only preclinical and clinical development while drug candidates are discovered somewhere else, typically by academic researchers or researchers from research institutes and brought in to NRDO companies.

Licensing to NDRO, by originators allows basic researchers to focus on expertise in their comort zone while NRDO can focus on area of its own strengths, clinical development.

Bridge Biotherapeutics, Inc., is a clinical stage, NRDO type biotech company founded 2015. Since its inception, it brought in three drug candidates and has been developing them to clinical stage. BBT-877, novel autotaxin inhibitor, was licensed from another biotech company, LegoChem Biosciences, back in 2017 and was put in clinic 2019. With its PK data and PD biomarker data from Phase 1 in healthy volunteers, it was licensed out to Boehringer Ingelheim at 1.1 billion Euro price tag.

In this presentation, NRDO business model is given to audience as one of commercialization strategy which basic research can consider for their innovations, and BBT-877 case will be given as successful case.